Solriamfetol Oral Tablet + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Excessive Sleepiness
Conditions
Excessive Sleepiness, Shift-work Disorder
Trial Timeline
Jul 21, 2021 → Apr 19, 2024
NCT ID
NCT04788953About Solriamfetol Oral Tablet + Placebo
Solriamfetol Oral Tablet + Placebo is a approved stage product being developed by Axsome Therapeutics for Excessive Sleepiness. The current trial status is terminated. This product is registered under clinical trial identifier NCT04788953. Target conditions include Excessive Sleepiness, Shift-work Disorder.
What happened to similar drugs?
1 of 4 similar drugs in Excessive Sleepiness were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04788953 | Approved | Terminated |
Competing Products
8 competing products in Excessive Sleepiness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + PF-03654746 | Pfizer | Phase 2 | 35 |
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 32 |
| Solriamfetol + Placebo | Axsome Therapeutics | Approved | 40 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 44 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 44 |
| Fibrin Sealant Grifols + EVICEL | Grifols | Phase 3 | 37 |
| ORX142 Tablets | Centessa Pharmaceuticals | Phase 1 | 33 |
| VSF-173 | Vanda Pharmaceuticals | Phase 2 | 25 |